ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Key facts

Sponsor

Nationwide Children's Hospital

Principal Investigator

Holly Lindsay, MD

Children's Hospital Colorado

Intervention

Tocilizumab(drug)

Enrollment

30 enrolled

Eligibility

1-39 years · All sexes

Timeline

2022 – 2029

Study locations (14)

• Children's Hospital Colorado, Aurora, Colorado, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• Nicklaus Children's Hospital, Miami, Florida, United States
• Duke Children's Hospital, Durham, North Carolina, United States
• Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
• Nationwide Children's Hospital, Columbus, Ohio, United States
• Texas Children's Hospital, Houston, Texas, United States
• Seattle Children's Hospital, Seattle, Washington, United States
• Sydney Children's Hospital, Randwick, New South Wales, Australia
• Queensland Children's Hospital, South Brisbane, Queensland, Australia
• Perth Children's Hospital, Perth, Western Australia, Australia
• Stollery Children's Hospital, Edmonton, Alberta, Canada
• The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
• McGill University Health Center, Montreal, Quebec, Canada

Collaborators

Children's Hospital Colorado

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adamantinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT05919264
  FOG-001 in Locally Advanced or Metastatic Solid Tumors
  Parabilis Medicines, Inc.
• RECRUITINGPHASE2NCT05286788
  MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
  Nationwide Children's Hospital
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT03970226
  Tocilizumab in Children With ACP
  University of Colorado, Denver

See all trials for Adamantinoma →